Background Combination immunotherapy development has largely focused on identifying complementary therapeutic components, with success often framed as a function of composition. While rational selection of agents is essential, clinical outcomes across solid tumors and cellular therapy platforms suggest that appropriate component selection alone is insufficient to ensure durable efficacy. In practice, therapies with strong mechanistic rationale frequently underperform despite targeting relevant immune pathways.
Kate Lynn Blatt (Mon,) studied this question.